JP5718807B2 - 自己抗体の除去による閉塞性血栓血管炎の治療 - Google Patents

自己抗体の除去による閉塞性血栓血管炎の治療 Download PDF

Info

Publication number
JP5718807B2
JP5718807B2 JP2011504387A JP2011504387A JP5718807B2 JP 5718807 B2 JP5718807 B2 JP 5718807B2 JP 2011504387 A JP2011504387 A JP 2011504387A JP 2011504387 A JP2011504387 A JP 2011504387A JP 5718807 B2 JP5718807 B2 JP 5718807B2
Authority
JP
Japan
Prior art keywords
patient
column
specific ligand
treatment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011504387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517690A (ja
JP2011517690A5 (enExample
Inventor
バウマン，ゲルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2011517690A publication Critical patent/JP2011517690A/ja
Publication of JP2011517690A5 publication Critical patent/JP2011517690A5/ja
Application granted granted Critical
Publication of JP5718807B2 publication Critical patent/JP5718807B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2011504387A 2008-04-18 2009-04-20 自己抗体の除去による閉塞性血栓血管炎の治療 Expired - Fee Related JP5718807B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08075309A EP2110140A1 (en) 2008-04-18 2008-04-18 Treatment of thromboangiitis obliterans by removal of autoantibodies
EP08075309.8 2008-04-18
PCT/EP2009/002993 WO2009143944A2 (en) 2008-04-18 2009-04-20 Treatment of thromboangiitis obliterans by removal of autoantibodies

Publications (3)

Publication Number Publication Date
JP2011517690A JP2011517690A (ja) 2011-06-16
JP2011517690A5 JP2011517690A5 (enExample) 2012-05-31
JP5718807B2 true JP5718807B2 (ja) 2015-05-13

Family

ID=39683905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011504387A Expired - Fee Related JP5718807B2 (ja) 2008-04-18 2009-04-20 自己抗体の除去による閉塞性血栓血管炎の治療

Country Status (7)

Country Link
US (1) US8663147B2 (enExample)
EP (2) EP2110140A1 (enExample)
JP (1) JP5718807B2 (enExample)
CN (1) CN102006888A (enExample)
CA (1) CA2721061C (enExample)
ES (1) ES2560456T3 (enExample)
WO (1) WO2009143944A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008365B2 (en) 2016-09-01 2021-05-18 National Institute Of Advanced Industrial Science And Technology Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1409245A1 (ru) 1985-04-12 1988-07-15 Научно-исследовательский институт травматологии и ортопедии Способ лечени врожденного вывиха бедра
SU1409275A1 (ru) * 1985-06-10 1988-07-15 Томский Медицинский Институт Способ лечени псориаза
ATE266415T1 (de) * 1995-11-15 2004-05-15 Edwards Lifesciences Corp Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern
RU2153168C2 (ru) 1997-11-25 2000-07-20 Научно-исследовательский институт кардиологии Способ определения показаний к проведению плазмафереза при лечении стенокардии
US6551266B1 (en) 1998-12-29 2003-04-22 Occulogix Corporation Rheological treatment methods and related apheresis systems
EP2228389B1 (en) * 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
DE102006003782A1 (de) 2006-01-25 2007-08-02 Protagen Ag Immunadsorptionstherapie mittels Autoantigenen
US20100047211A1 (en) * 2006-05-19 2010-02-25 The Johns Hopkins University Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
US8088600B2 (en) * 2006-10-18 2012-01-03 Centocor Ortho Biotech Inc. Nucleic acids encoding cynomolgus IL-13 mutein proteins
WO2008151847A1 (en) 2007-06-13 2008-12-18 Max-Delbrück-Centrum für Molekulare Medizin Autoantibody binding peptides and their use for the treatment of vascular diseases

Also Published As

Publication number Publication date
JP2011517690A (ja) 2011-06-16
ES2560456T3 (es) 2016-02-19
US8663147B2 (en) 2014-03-04
CN102006888A (zh) 2011-04-06
WO2009143944A2 (en) 2009-12-03
CA2721061C (en) 2016-06-28
EP2288384A2 (en) 2011-03-02
EP2110140A1 (en) 2009-10-21
CA2721061A1 (en) 2009-12-03
WO2009143944A3 (en) 2010-08-05
US20110105980A1 (en) 2011-05-05
EP2288384B1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
RU2014106652A (ru) Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
Chaung et al. Mitochondrial transcription factor A is a proinflammatory mediator in hemorrhagic shock
JP2002504831A (ja) 自己抗体の除去による心筋症の処置
RU2201255C1 (ru) Лекарственное средство и способ регуляции сосудистого тонуса
CN1160126C (zh) 败血症治疗用免疫吸附剂
BR112020005450A2 (pt) aglutinante antiadrenomedulina (adm) para uso em terapia ou prevenção dos sintomas de doença
JP2020504110A5 (enExample)
JP2020513757A5 (enExample)
JP5718807B2 (ja) 自己抗体の除去による閉塞性血栓血管炎の治療
CA1090701A (fr) Medicament permettant de traiter les infections aigues ou chroniques dues au virus de l'hepatite b
Ohning et al. Differential kinetics for immunoneutralization of circulating gastrin by gastrin monoclonal antibody and its Fab1 fragment in rats
JP2001509517A (ja) 微小循環障害の治療及び／又は予防のための薬剤
PT1495056E (pt) Métodos de análise
Russell et al. Therapeutic thoracic duct drainage: a systematic review of the eastern European experience and future potential
Ptak et al. Immunoadsorption therapy and complement activation
US20090196938A1 (en) Use of a matrix for removing c-reactive protein from biological fluids
ES2784842T3 (es) Objetivo dual de TAFI y PAI-1
RU2525280C1 (ru) Способ реконструкции инфраренального отдела брюшной аорты по поводу аневризмы
Nishiyama et al. Blue Toe Syndrome Responding to Direct Hemoadsorption Therapy with the Rheocarna® Device: A Case Report
Bambauer¹ et al. Therapeutic Apheresis in Dyslipidemia
Farmer et al. Studies of family history among patients with inflammatory bowel disease
Xue Treatment of Metabolic Diseases by Hemoperfusion
Bambauer et al. Dyslipoproteinemia therapy with lipoprotein-apheresis and/or human monoclonal antibodies
Fischer et al. A possible role for vasoactive intestinal peptide (VIP) in the hypotension associated with aortic unclamping
Faloon et al. Significance of renin and aldosterone in cirrhotic patients receiving spironolactone and furosemide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150319

R150 Certificate of patent or registration of utility model

Ref document number: 5718807

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees